Research & Literature

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.

Ben Ami E, Demetri GD

Expert opinion on drug safety 2016; (15(4)):571-8 doi:10.1517/14740338.2016.1152258.

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML).

El Jurdi N, Bankoff M, Klein A, Saif MW

Cureus 2016; (8(6)):e660 doi:10.7759/cureus.660.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, et al.

Annals of hematology 2017; (96(9)):1463-1470 doi:10.1007/s00277-017-3067-x.

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.

Zhang Y, Gao Y, Zhang H, et al.

Blood 2018; (131(20)):2256-2261 doi:10.1182/blood-2017-11-817510.

Imatinib Mesylate.

Waller CF

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2018; (212()):1-27 doi:10.1007/978-3-319-91439-8_1.

A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).

Iriyama N, Takahashi H, Naruse H, et al.

Molecular genetics & genomic medicine 2019; (7(4)):e00591 doi:10.1002/mgg3.591.

Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.

Bielorai B, Leitner M, Goldstein G, et al.

Acta haematologica 2019; (141(2)):119-127 doi:10.1159/000495687.

A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA.

Zanelli M, Smith M, Zizzo M, et al.

BMC pulmonary medicine 2019; (19(1)):216 doi:10.1186/s12890-019-0967-7.

Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms.

Fang H, Tang G, Loghavi S, et al.

Histopathology 2020; (76(7)):1042-1054 doi:10.1111/his.14097.

Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing.

Zimmermann N, Nassiri M, Zhou J, et al.

Cancer genetics 2020; (244()):55-59 doi:10.1016/j.cancergen.2020.03.002.

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.

Patnaik MM, Lasho T

Hematology. American Society of Hematology. Education Program 2020; (2020(1)):460-464 doi:10.1182/hematology.2020000163.

Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.

Xu X, Lu Q, Wang Z, et al.

Cancer research and treatment 2021; (53(3)):889-892 doi:10.4143/crt.2020.1272.

Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports.

Wang SC, Yang WY

World journal of clinical cases 2021; (9(1)):204-210 doi:10.12998/wjcc.v9.i1.204.

Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor β: A case report.

Li Y, Jing Y, Wan H, Liu D

Medicine 2021; (100(8)):e24707 doi:10.1097/MD.0000000000024707.

World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.

Shomali W, Gotlib J

American journal of hematology 2022; (97(1)):129-148 doi:10.1002/ajh.26352.

A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the PDGFRB Gene and Successfully Treated with Imatinib.

Borogovac A, Sahu KK, Vishwanathan GK, et al.

Cancer management and research 2021; (13()):8841-8847 doi:10.2147/CMAR.S324718.

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.

Di Giacomo D, Quintini M, Pierini V, et al.

Annals of hematology 2022; (101(2)):297-307 doi:10.1007/s00277-021-04712-8.

Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.

Patnaik MM, Tefferi A

American journal of hematology 2022; (97(3)):352-372 doi:10.1002/ajh.26455.

Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features.

Su Z, Liu X, Hu W, et al.

Hematology (Amsterdam, Netherlands) 2022; (27(1)):1010-1018 doi:10.1080/16078454.2022.2117206.

Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.

Cheng F, Zeng F, Li Q, et al.

Cancer 2022; (128(22)):3951-3958 doi:10.1002/cncr.34478.

Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.

Voeller J, DeNapoli T, Griffin TC

Cancer reports (Hoboken, N.J.) 2022; (5(11)):e1710 doi:10.1002/cnr2.1710.

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience.

Swain TR, Goutam S, Jena RK, Rout N

Indian journal of pharmacology 2022; (54(5)):349-352 doi:10.4103/ijp.ijp_844_21.

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy.

Qu S, Yan Y, Li C, et al.

Leukemia research reports 2023; (19()):100367 doi:10.1016/j.lrr.2023.100367.

The international consensus classification of eosinophilic disorders and systemic mastocytosis.

Wang SA, Orazi A, Gotlib J, et al.

American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

Metzgeroth G, Steiner L, Naumann N, et al.

Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.

Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene: A Rare Case of Poor Response to Imatinib and Possible Transformation Mechanisms from Myeloid Neoplasms of Bone Marrow to T-Cell Lymphoblastic Lymphoma Invasion in Lymph Nodes.

Gou Y, Tang Y, Liu S, et al.

Journal of inflammation research 2023; (16()):5163-5170 doi:10.2147/JIR.S427995.

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

Reiter A, Metzgeroth G, Cross NCP

Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies.

Ngo TQ, Goh AFN, Dorwal P, et al.

Pathology 2025; (57(3)):340-347 doi:10.1016/j.pathol.2024.09.009.

MPRIP::PDGFRB Fusion Gene: A Rare Case Report of Adult Myeloid/Lymphoid Neoplasm With Eosinophilia and Tyrosine Kinase Gene Fusions.

Ukkahad T, Thamgrang T

Case reports in hematology 2025; (2025()):7098722 doi:10.1155/crh/7098722.

Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.

Ye F, Wang L, Qian Y, et al.

Annals of hematology 2025; (104(10)):5507-5512 doi:10.1007/s00277-025-06620-7.

Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusion.

Tripodi J, Tremblay D, Ahire D, Najfeld V

Molecular cytogenetics 2025; (18(1)):28 doi:10.1186/s13039-025-00730-7.

Resistance to imatinib in a ETV6::PDGFRB rearranged myeloid/lymphoid neoplasm with high-risk mutations: a case report.

Cavelier L, Saft L, Sander B, Deneberg S

Frontiers in oncology 2025; (15()):1611747 doi:10.3389/fonc.2025.1611747.

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Hanna C, Rizkallah J, Charbel N, et al.

Current hematologic malignancy reports 2026; (21(1)).

MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.

Gao M, Bachiashvili K, Jamy O, et al.

Annals of hematology 2026; (105(5)).

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (FIP1L1::PDGFRA) complicated by Loeffler's endocarditis leading to stroke.

Luo R, Qi X

BMC neurology 2026; (26(1)).

CCDC88C::PDGFRB-rearranged myeloid neoplasm with predominant neutrophilia and rapid response to imatinib: a molecularly defined case report.

Guo Y, Wu H, Cai Z, et al.

Frontiers in oncology 2026; (16()):1855322 doi:10.3389/fonc.2026.1855322.

KCTD5::PDGFRB Fusion Gene Leading to Clonal Hypereosinophilia With Cardiac Involvement in a Young Adult: A Case Report.

de Groote L, Papazoglou D, Ku J, et al.

Case reports in hematology 2026; (2026()):6882482 doi:10.1155/crh/6882482.